Endothelial progenitor cell response to antiproliferative drug exposure

Atherosclerosis

Volumn 225, Issue 1, 2012, Pages 91-98

  Banerjee, Subhash ^a,b   Xu, Hao ^a   Fuh, Eric ^b   Nguyen, Kytai T ^c   Garcia, Joseph A ^a,b   Brilakis, Emmanouil S ^a,b   Bhatt, Deepak L ^d  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b Veterans Affairs North Texas Veterans Health Care Center   (United States)

^c UNIVERSITY OF TEXAS AT ARLINGTON   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Antiproliferative drugs; Drug eluting stent; Endothelial progenitor cell

Indexed keywords

EVEROLIMUS; NITRIC OXIDE; PACLITAXEL; PROSTACYCLIN; PROTHROMBIN; RAPAMYCIN; ZOTAROLIMUS;

ADULT; ANIMAL CELL; ANTICOAGULATION; APOPTOSIS; ARTICLE; CELL ADHESION; CELL FUNCTION; CELL MIGRATION; CELL PROLIFERATION; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; ENDOTHELIAL PROGENITOR CELL; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; SHEAR STRESS;

ANIMALS; APOPTOSIS; CELL ADHESION; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CORONARY RESTENOSIS; DRUG-ELUTING STENTS; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EPOPROSTENOL; HUMANS; MALE; NITRIC OXIDE; PACLITAXEL; RATS; SIROLIMUS; STEM CELLS; STENTS;

EID: 84867874811     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2012.08.025     Document Type: Article

References (30)

1. Costa M.A., Simon D.I. Molecular basis of restenosis and drug-eluting stents. Circulation 2005, 111:2257-2273.
2. Bavry A.A., Kumbhani D.J., Helton T.J., Borek P.P., Mood G.R., Bhatt D.L. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med 2006, 119:1056-1061.
3. Stettler C., Wandel S., Allemann S., Kastrati A. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007, 370:937-948.
4. Bavry A.A., Bhatt D.L. Appropriate use of drug-eluting stents: balancing the reduction in restenosis with the concern of late thrombosis. Lancet 2008, 371:2134-2143.
5. Notaristefano S., Sbarzaglia P., Cavallini C. Late stent thrombosis after drug-eluting stent implantation: epidemiological, clinical and pathophysiological aspects. G Ital Cardiol (Rome) 2008, 9:674-683.
6. Joner M., Finn A.V., Farb A., Mont E.K., Virmani R. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006, 48:193-202.
7. Joner M., Nakazawa G., Finn A.V., et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008, 52:333-342.
8. Xie Y., Takano M., Murakami D., et al. Comparison of neointimal coverage by optical coherence tomography of a sirolimus-eluting stent versus a bare-metal stent three months after implantation. Am J Cardiol 2008, 102:27-31.
9. Yao Z.H., Matsubara T., Inada T., Suzuki Y., Suzuki T. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography. Chin Med J (Engl) 2008, 121:503-507.
10. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997, 275:964-967.
11. Clever Y.P., Cremers B., Kraub B., et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention 2011, 7:k32-k42.
12. Manjappan N., Agarwal A., Cavusoglu E. Very late bare-metal stent thrombosis. A case report and review of the literature. J Invasive Cardiol 2006, 18:203-206.
13. Banerjee S., Brilakis E., Zhang S., et al. Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis 2006, 189:70-75.
14. Chen Y.H., Lin S.J., Lin F.Y., et al. High glucose impairs early and late endothelial progenitor cells by modifying nitric oxide-related but not oxidative stress-mediated mechanisms. Diabetes 2007, 56:1559-1568.
15. Kamath K.R., Barry J.J., Miller K.M. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006, 58:412-436.
16. Parry T.J., Brosiu R., Thyagarajan R., et al. Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries. Eur J Pharmacol 2005, 524:19-29.
17. Tulis D.A. Rat carotid artery balloon injury model. Methods Mol Med 2007, 139:1-30.
18. Lundberg J.O., Weitzberg E., Gladwin M.T. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov 2008, 7:156-167.
19. Nguyen K.T., Eskin S.G., Patterson C., Runge M.S., McIntire L.V. Shear stress reduces protease activated receptor-1 expression in human endothelial cells. Ann Biomed Eng 2001, 29:145-152.
20. Byrne R.A., Joner M., Kastrati A. Polymer coatings and delayed arterial healing following drug-eluting stent implantation. Minerva Cardioangiol 2009, 57:567-584.
21. Kim J.S., Kim T.H., Fan C., et al. Comparison of neointimal coverage of sirolimus-eluting stents and paclitaxel-eluting stents using optical coherence tomography at 9 months after implantation. Circ J 2010, 74:320-326.
22. Nakazawa G., Finn A.V., John M.C., Kolodgie F.D., Virmani R. The significance of preclinical evaluation of sirolimus-, paclitaxel-, and zotarolimus-eluting stents. Am J Cardiol 2007, 100:36M-44M.
23. Guagliumi G., Sirbu V., Bezerra H., et al. Strut coverage and vessel wall response to zotarolimus-eluting and bare-metal stents implanted in patients with ST-segment elevation myocardial infarction: the OCTAMI (Optical Coherence Tomography in Acute Myocardial Infarction) Study. JACC Cardiovasc Interv 2010, 3:680-687.
24. Palmerini T., Biondi-Zoccai G., Della Riva D., et al. Stent thrombosis with drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. Lancet 2012, 379:1393-1402.
25. Radomski M.W., Palmer R.M.J., Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987, 2:1057-1058.
26. 2, and prostacyclin. Pharmacol Rev 1979, 30:293-331.
27. Marcum J.A., Rosenberg R.D. Heparin-like molecules with anti-coagulant activity are synthesized by cultured endothelial cell. Biochem Biophys Res Commun 1985, 126:365-372.
28. Chan T.K., Chan V. Antithrombin III, the major modulator of intravascular coagulation, is synthesized by human endothelial cells. Thromb Haemost 1981, 46:504-506.
29. Esmon N.L., Carroll R.C., Esmon C.T. Thrombomodulin blocks the ability of thrombin to activate platelets. J Biol Chem 1983, 258:12238-12242.
30. Merchan J.R., Jayaram D.R., Supko J.G., He X.Y., Bubley G.J., Sukhatme V.P. Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition. Int J Cancer 2005, 113:490-498.